Sign in

CIK 0001880438 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

AN2 Therapeutics, Inc.

Sign in to watch
Ticker
ANTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
820606654
Phone
(650) 331-9090
Business address
1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
Open-market buys, last 90 days
$11,602
in 1 filing
Open-market sales, last 90 days
$117,428
in 4 filings, $104K under 10b5-1 plans

Net −$105,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 94 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2024-11-19 Readnour Robin Shane Director Purchase +75,000 $1.04 $78K 489,788
2024-11-19 Zakrzewski Joseph S Director Purchase +5,000 $1.01 $5K 123,199
2024-11-18 Zakrzewski Joseph S Director Purchase +20,000 $1.00 $20K 118,199
2024-11-18 Easom Eric Chief Executive Officer Purchase +50,000 $1.00 $50K 1,065,766
2024-11-04 Prior Stephen David Chief Strategy Officer Grant or award +10,125 35,342
2024-11-04 Prior Stephen David Chief Strategy Officer Grant or award · Stock Option (right to buy) +20,250 20,250
2024-11-04 Eizen Joshua M See Remarks Grant or award +31,500 126,335
2024-11-04 Eizen Joshua M See Remarks Grant or award · Stock Option (right to buy) +63,000 63,000
2024-08-14 Leonard Braden Michael 10% owner Purchase +1,500,000 $1.04 $1.6M 5,749,432
2024-08-09 RA CAPITAL MANAGEMENT, L.P. 10% owner Sale −3,410,335 $1.08 $3.7M 1,725,348
2024-08-09 RA CAPITAL MANAGEMENT, L.P. 10% owner Sale −114,759 $1.08 $124K 300,853

Page 10 of 10 · 191 trades